DEA Telemedicine Rules Through 2026: What Controlled-Substance Telehealth Means for Payment Processing
Remote prescribing of controlled substances runs on a temporary DEA extension that ends with 2026. Processors underwriting these programs want to know what you prescribe and what you'll do on January 1, 2027.
As of November 15, 2026, DEA's COVID-19 telemedicine flexibilities for prescribing controlled medications run through December 31, 2026, under a fourth temporary extension. Without them, the Ryan Haight Act default generally requires at least one in-person medical evaluation before a controlled substance is prescribed remotely. For payments, that puts your prescribing model, and your plan for January 1, 2027, into underwriting.
The Ryan Haight Act (the Ryan Haight Online Pharmacy Consumer Protection Act of 2008) is the federal law whose default rule generally requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance remotely. DEA's temporary COVID-19 telemedicine flexibilities have allowed remote prescribing without that evaluation while they remain in force.
Where DEA's telemedicine rules stand in November 2026
As of November 15, 2026: the fourth temporary extension of DEA's telemedicine flexibilities (Federal Register, December 31, 2025, document 2025-24123) runs through December 31, 2026. DEA proposed a special registration for telemedicine on January 17, 2025 (90 FR 6541). A final rule was reported sent to the Office of Information and Regulatory Affairs on August 25, 2026, and had not been published as of mid-November 2026, according to our search.
Three things are moving at once, and they don't move together:
- The extension is temporary and dated. It has been extended four times, which is a pattern, not a promise.
- The special registration exists only as a proposal. The January 2025 proposal described three registration types, including one for telemedicine platforms. What a final rule contains won't be known until it is published.
- The default is the statute itself, which applies whenever no flexibility or registration covers the prescription.
This is a general summary of where the rules stand, not legal advice. Whether a particular prescribing model qualifies under any of them is a question for counsel who knows your program.
What the Ryan Haight default would mean for a remote-only program
It would generally put an in-person evaluation in front of remote prescribing of controlled substances. For a program built entirely on video or asynchronous visits, that changes the product: either patients see a clinician in person at some point, or the program relies on a route the law allows, and identifying those routes is your counsel's job, not your processor's.
For payments the issue is narrower and more mechanical. A program that may have to change how it delivers care on a fixed date has a known date on which some of what it sold could become undeliverable as described. Anything a patient has paid for beyond that date is exposure until the rules are settled.
Which telehealth prescriptions are controlled substances?
Several that telehealth programs build around. The schedules below are DEA's.
| Medication | DEA schedule | Telehealth programs that may prescribe it |
|---|---|---|
| Amphetamine | Schedule II | ADHD programs |
| Methylphenidate | Schedule II | ADHD programs |
| Testosterone | Schedule III | Men's health and hormone programs |
| Ketamine | Schedule III | Mental health programs |
| Buprenorphine | Schedule III | Opioid use disorder treatment programs |
If anything on your formulary isn't on this list and you're unsure of its status, check DEA's schedules in 21 CFR part 1308 before launch. Finding out during underwriting is worse.
Why processors ask about controlled substances
Because a temporary rule with an end date is a business-continuity question, and the acquirer answers for what its merchants process. Our reading of the underwriting logic runs like this:
- Continuity. If the core sale depends on a flexibility that ends on a known date, the processor needs to know what happens to the business, and to patients who've paid ahead, after that date.
- Network exposure. Visa §1.9.1.4 lets Visa permanently prohibit a merchant, or its principals, for non-compliance with the Visa Integrity Risk Program, including "illegal or brand-damaging" transaction activity. Prescribing outside what the law allows is the kind of activity an acquirer can't afford to be processing.
- Pharmacy sales. If you dispense as well as prescribe, non-face-to-face pharmaceutical sales under MCC 5912 are treated by Visa as high-integrity risk, which means the acquirer must hold Visa's high-integrity risk registration and must register you as a merchant unless you're accredited by NABP or another body Visa recognizes.
Controlled substances are one of several factors that move a telehealth business up the risk scale; the rest are in is telehealth a high-risk business for payment processors.
What underwriters ask a controlled-substance telehealth company
They want the prescribing model in enough detail to judge it, and the plan for when the rules change. Expect questions like these:
- Which controlled substances you prescribe, and their schedules.
- Who prescribes: names, state licenses and DEA registrations.
- Whether any patients have an in-person evaluation, and how that is recorded.
- Which pharmacies fill the prescriptions, and whether you dispense anything yourself.
- Your plan for January 1, 2027, under each outcome described below.
- How patients pay: per visit, monthly or prepaid, and how far ahead.
- How your marketing describes getting a prescription.
- Your dispute and refund history, if you've processed before.
These sit alongside the standard documents in the telehealth merchant account application checklist. Answering the January 2027 question in writing, before anyone asks, tells an underwriter you've thought about it.
Planning for January 1, 2027
Plan for three possible outcomes. This is risk planning from the payments side: the table doesn't forecast what DEA will do, and it isn't legal advice.
| If this happens | What it means for prescribing | Payments steps |
|---|---|---|
| DEA extends the flexibilities again | Remote prescribing continues on the new notice's terms and dates | Read the new end date; re-check how far ahead patients pay against it; tell your processor |
| A final special-registration rule is published | Conditions come from the final text and its effective date, not the 2025 proposal | Work out which registration you'd need and when; tell your processor which one you'll hold |
| The flexibilities lapse with nothing in their place | The Ryan Haight default generally requires an in-person evaluation first | Stop selling remote-only controlled-substance plans that run past the date; handle prepaid patients under the refund policy they accepted |
The billing rule we would apply in the meantime: don't sell prepaid controlled-substance care that runs past a date you can't be sure of delivering through. Monthly billing costs some upfront cash. It also keeps your refund exposure, and the reserve a processor sizes against it, tied to one month rather than to a regulatory calendar.
Platforms have a separate question. The 2025 proposal included a registration for telemedicine platforms, so a company that connects patients to prescribers, rather than employing them, should follow the final rule closely. If you're still choosing between being a clinic and being a platform, the order of decisions is in starting a telehealth company: the payments decisions.
VyaPay runs its own processor and underwrites in-house. If DEA publishes something in late December, you explain your plan to the team that makes the underwriting call, with nobody in between to relay it. Talk to VyaPay about your program.
Frequently asked questions
When do the DEA telemedicine flexibilities end?
Under the fourth temporary extension, published December 31, 2025, they run through December 31, 2026. That was still the end date as of mid-November 2026; any later change would come in a new Federal Register notice.
Has DEA finalized the special registration for telemedicine?
Not as of mid-November 2026, according to our search. DEA proposed it on January 17, 2025, and a final rule was reported to have gone to the Office of Information and Regulatory Affairs in August 2026.
Do the DEA flexibilities affect non-controlled prescriptions?
The flexibilities concern controlled medications. Prescribing other drugs by telehealth sits outside them, though it has its own rules that your counsel should review.
Will a processor accept a telehealth company that prescribes controlled substances?
That depends on the processor and the file. An underwriter will look at the specifics: what is prescribed, by whom, with what evaluation, and what happens after December 31, 2026. No processor can tell you the answer before it has seen the file.
Sources
- Federal Register, DEA and HHS, fourth temporary extension of COVID-19 telemedicine flexibilities for controlled medications, December 31, 2025 (document 2025-24123)
- DEA, proposed rule on special registration for telemedicine, 90 FR 6541, January 17, 2025
- Legal Information Institute, 21 U.S.C. 829 (prescriptions, including the Ryan Haight Act provisions)
- Legal Information Institute, 21 CFR part 1308 (schedules of controlled substances)
- Visa, Visa Core Rules and Visa Product and Service Rules, 24 October 2026 (sections 1.9.1.4 and 1.9.5.1)
